Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
Mattia GalliStefano BenenatiFrancesco FranchiFabiana RolliniDavide CapodannoGiuseppe Biondi-ZoccaiGiovanni Maria VescovoLarisa H CavallariBehnood BikdeliJurrien Ten BergRoxana MehranCharles Michael GibsonFilippo CreaNaveen L PereiraDirk SibbingDominick J AngiolilloPublished in: European heart journal (2022)
A guided selection of P2Y12-inhibiting therapy represents the strategy associated with the most favourable balance between safety and efficacy. These findings support a broader adoption of guided P2Y12 inhibiting therapy in patients with acute coronary syndrome.